Printer Friendly

deBethizy Named Chairman at Rigontec.

MANews-(C)2009-2015

- Dr. J. Donald deBethizy has been appointed as chairman of German biopharmaceutical company Rigontec GmbH's board of directors, the company said on Wednesday.

He replaces outgoing chairman Prof. Dr. Gunther Hartmann who co-founded Rigontec and led the board since 2014. Prof. Hartmann will remain on the board of directors.

DeBethizy brings more than 30 years of experience in research and development, as well as financial and operational management in the biotechnology and consumer products industry.

He is currently president of White City Consulting ApS in Denmark and serves on the supervisory boards of arGEN-X NV (Euronext Brussels), Newron Pharmaceuticals SPA (SIX Swiss Exchange), Serendex Pharmaceuticals (Oslo Exchange) and Noxxon Pharma AG.

Previously, deBethizy served as president and CEO of Santaris Pharma A/S until the company was sold to Roche, and as Executive chairman of Contera Pharma until it was sold to Bukwang Pharma in November 2014.

He was also co-founder and CEO of Targacept, Inc., a public US biotechnology company listed on NASDAQ. He recently served on the supervisory boards of LigoCyte Pharma, Enbiotix and Biosource.

Rigontec is a privately held German biopharmaceutical company developing RNA-based immunotherapeutics for the treatment of cancer and viral diseases.

The company is developing synthetic ligands of a novel receptor of the innate immune system, Retinoic acid Inducible Gene I (RIG-I), which recognizes viral RNA.

COPYRIGHT 2015 Normans Media Ltd.
No portion of this article can be reproduced without the express written permission from the copyright holder.
Copyright 2015 Gale, Cengage Learning. All rights reserved.

Article Details
Printer friendly Cite/link Email Feedback
Publication:M & A Navigator
Date:Jul 15, 2015
Words:224
Previous Article:Apogenix Inks China, Macao, and Hong Kong Licensing Pact with CANbridge Life Sciences.
Next Article:WPX Energy to Acquire Permian Basin Producer RKI for USD 2.35bn.
Topics:

Terms of use | Privacy policy | Copyright © 2020 Farlex, Inc. | Feedback | For webmasters